These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 22918925)

  • 21. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current state of vaccine therapies in non-small-cell lung cancer.
    Romero P
    Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S28-36. PubMed ID: 18540532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.
    Shepherd FA; Douillard JY; Blumenschein GR
    J Thorac Oncol; 2011 Oct; 6(10):1763-73. PubMed ID: 21876456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
    Yi JS; Ready N; Healy P; Dumbauld C; Osborne R; Berry M; Shoemaker D; Clarke J; Crawford J; Tong B; Harpole D; D'Amico TA; McSherry F; Dunphy F; McCall SJ; Christensen JD; Wang X; Weinhold KJ
    Clin Cancer Res; 2017 Dec; 23(24):7474-7482. PubMed ID: 28951518
    [No Abstract]   [Full Text] [Related]  

  • 30. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emepepimut-S for non-small cell lung cancer.
    Corrales-Rodriguez L; Blais N; Soulières D
    Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
    Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
    Adam V; Wauters I; Vansteenkiste J
    Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.
    Heigener D; Reck M
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):69-83. PubMed ID: 25199617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
    Tyagi P; Mirakhur B
    Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing the immune system for the treatment of non-small-cell lung cancer.
    Brahmer JR
    J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
    Forde PM; Reiss KA; Zeidan AM; Brahmer JR
    Oncologist; 2013; 18(11):1203-13. PubMed ID: 24105749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
    Decoster L; Wauters I; Vansteenkiste JF
    Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of immunotherapy in stage III nonsmall cell lung cancer.
    Wrona A
    Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.